Diane Eaton

TL;DR: Apixaban 5 mg twice daily was ranked the highest for most outcomes, and was cost effective compared with warfarin, and the network meta-analysis informs the choice of DOACs for prevention of stroke in patients with atrial fibrillation.

TL;DR: For acute treatment and secondary prevention of VTE, there is little evidence that NOACs offer an efficacy advantage over warfarin, but the risk of bleeding complications was lower for someNOACs than for warfarIn, and cost-effectiveness was lower than for other interventions.

TL;DR: A systematic review of the diagnostic test accuracy (DTA) of screening tests for AF and an economic model to compare the cost-effectiveness of different screening strategies were developed, found systematic opportunistic screening was more likely to be cost-effective than systematic population screening.

TL;DR: A cost-effectiveness model to compare warfarin with directly acting (or non–vitamin K antagonist) oral anticoagulants in patients with non-valvular atrial fibrillation in England and Wales found apixaban had the highest expected net benefit and greatest probability of having highest net benefit, but there was considerable uncertainty between DOACs.

TL;DR: Prevention of stroke in atrial fibrillation in England and Wales H. Thom, J. LópezLópez, G. Savovic, and A. Stephens-Boal.